Clinical studies with paclitaxel - eluting stent systems

Area of Science:

• Interventional Cardiology
• Biomaterials Science
• Pharmacology

Background:

• Coronary artery stents improve lumen diameter but do not eliminate restenosis, which is caused by neointimal hyperplasia.
• Paclitaxel was identified as an effective antineoplastic compound to limit neointimal hyperplasia.
• Local delivery of paclitaxel to the arterial wall showed promise in animal models.

Purpose of the Study:

• To evaluate the efficacy and safety of paclitaxel-eluting coronary stents in preventing restenosis.
• To assess the role of paclitaxel in limiting neointimal hyperplasia after stenting.

Main Methods:

• Development and FDA approval of paclitaxel-eluting stents based on pivotal TAXUS trials.
• Utilizing polymer coatings or direct drug impregnation for paclitaxel delivery.
• Analysis of randomized trials and registry data across various patient and lesion subsets.

Main Results:

• Paclitaxel-eluting stents demonstrated effectiveness in preventing restenosis across diverse patient and lesion types.
• Pooled data analyses confirmed an acceptable safety profile, despite concerns regarding vascular healing and stent thrombosis.
• Current generation stents show performance differences compared to sirolimus-eluting stents, though clinical relevance is debated.

Conclusions:

• Paclitaxel-eluting coronary stents are effective in preventing restenosis and have an acceptable safety profile.
• Ongoing advancements in elution techniques and stent architecture may further enhance performance.
• Paclitaxel's unique position as a non-limus antiproliferative agent highlights its future importance in vascular medicine.